OneAscent Financial Services LLC Acquires Shares of 15,129 AxoGen, Inc. (NASDAQ:AXGN)

OneAscent Financial Services LLC acquired a new stake in shares of AxoGen, Inc. (NASDAQ:AXGN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,129 shares of the medical equipment provider’s stock, valued at approximately $249,000.

A number of other institutional investors also recently modified their holdings of AXGN. Arrowstreet Capital Limited Partnership raised its holdings in shares of AxoGen by 37.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 97,290 shares of the medical equipment provider’s stock valued at $1,603,000 after acquiring an additional 26,298 shares in the last quarter. Norges Bank bought a new position in AxoGen in the 4th quarter worth $1,269,000. LPL Financial LLC purchased a new stake in shares of AxoGen in the 4th quarter worth about $210,000. Fox Run Management L.L.C. bought a new stake in shares of AxoGen during the 4th quarter valued at about $169,000. Finally, Sei Investments Co. purchased a new position in shares of AxoGen during the fourth quarter valued at about $188,000. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other AxoGen news, insider Erick Wayne Devinney sold 15,111 shares of AxoGen stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total value of $264,442.50. Following the completion of the transaction, the insider now directly owns 217,762 shares of the company’s stock, valued at approximately $3,810,835. The trade was a 6.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Amy Mcbride Wendell sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the completion of the transaction, the director now owns 97,899 shares in the company, valued at approximately $1,959,937.98. This represents a 4.86 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company’s stock.

AxoGen Stock Performance

AxoGen stock opened at $16.22 on Friday. AxoGen, Inc. has a twelve month low of $5.55 and a twelve month high of $21.00. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $719.26 million, a P/E ratio of -50.69 and a beta of 1.02. The stock’s 50 day moving average is $18.16 and its 200 day moving average is $15.96.

Analyst Ratings Changes

Several analysts have commented on the stock. Lake Street Capital began coverage on shares of AxoGen in a report on Monday, March 17th. They issued a “buy” rating and a $30.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $24.00 price target on shares of AxoGen in a research report on Wednesday, March 5th. Finally, Canaccord Genuity Group increased their price objective on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, February 26th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $22.60.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.